The preclinical Alzheimer cognitive composite: measuring amyloid-related decline - Wikidata - awgldk - TriplyDB

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

http://www.wikidata.org/entity/Q34422469

about

Revolutionizing Alzheimer's disease and clinical trials through biomarkers Update on Disease-Modifying/Preventive Therapies in Alzheimer’s Disease The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans Drug development in Alzheimer's disease: the path to 2025 Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.Three dimensions of the amyloid hypothesis: time, space and 'wingmen'Imaging plus X: multimodal models of neurodegenerative disease.Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease.Use of High-Frequency In-Home Monitoring Data May Reduce Sample Sizes Needed in Clinical Trials.Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.Mild Cognitive Impairment in Late Middle Age in the Wisconsin Registry for Alzheimer's Prevention Study: Prevalence and Characteristics Using Robust and Standard Neuropsychological Normative Data.The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.Study protocol: Insight 46 - a neuroscience sub-study of the MRC National Survey of Health and Development.A Rehabilomics framework for personalized and translational rehabilitation research and care for individuals with disabilities: Perspectives and considerations for spinal cord injury.Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease.The evolution of preclinical Alzheimer's disease: implications for prevention trials.Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals.Brain structure and function as mediators of the effects of amyloid on memory.Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span.Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings.Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force.Establishing Composite Cognitive Endpoints for Use in Preclinical Alzheimer's Disease Trials.Subjective and objective cognitive function among older adults with a history of traumatic brain injury: A population-based cohort study.Cognitive/Clinical Endpoints for Pre-Dementia AD Trials.Risk of dementia and death in the long-term follow-up of the Pittsburgh Cardiovascular Health Study-Cognition Study.The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials.A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS).CAP--advancing the evaluation of preclinical Alzheimer disease treatments.Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit.Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score.Early detection of cryptic memory and glucose uptake deficits in pre-pathological APP mice Glycemic control, cognitive function, and family support among middle-aged and older Hispanics with diabetes: The Hispanic Community Health Study/Study of Latinos Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study.Allocentric Spatial Memory Testing Predicts Conversion from Mild Cognitive Impairment to Dementia: An Initial Proof-of-Concept Study.Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward.

P2860

Q26744882-13F6EC44-41F3-4C24-90D9-CDC6DD08001F Q26778668-D9D545A7-91D0-4ED6-ABF6-69E7DB57628F Q26801640-9F544C5C-4ADF-4694-85C4-9820F45DA3A3 Q26801647-AB8F7BFF-82B8-4609-AEDF-DD273664F152 Q26801657-F7B4BCCA-B979-4876-B887-C52D9EABEE84 Q27007748-89376286-4775-45DC-9351-F68C7CDC3F05 Q27331605-DA57999F-424E-4D3B-B1F3-D474E5AE99B5 Q27333870-90B8AD2F-0C49-4AE5-8AEF-A6B1287DAC06 Q28082768-2156F6EE-1FCA-441A-8F84-1FF3D1F1A475 Q30491715-998A1193-3695-4BD7-AE3B-7AC41AE10B06 Q30754529-FD72FB57-7BF0-4E84-8648-6C972BAA3F44 Q30994007-4080B8AB-E811-4861-A309-A6FC9FB3CCA6 Q30996727-1D14132F-C4B4-401D-8DBF-DF435449637F Q31097104-7F2DAE3C-30B1-4E74-B7D2-4A0C6190A97F Q31147579-D25205AA-3E9D-485C-A5A3-2B86AD664A92 Q33576727-69C84215-F9D1-42AF-830A-71788B3DC3C8 Q34197843-8EBBD59D-6C63-40A9-90E6-D5C504DA1B40 Q34477459-1050A59C-1C30-4931-AE96-95CB38743356 Q34849048-0D0C4CD6-D274-46F7-9B0C-765A1BD6BE16 Q34940642-A66A1FCF-0EEC-459D-9651-77CEA3E3F795 Q35211063-7DA4CE51-BC11-4444-B9AF-6F0BD41CEA3C Q35418054-A1985FEE-F5B5-4EC5-AAC6-B9E348B142B1 Q35598271-DB12E052-1C53-4DC6-BAEB-04321AE77D92 Q35889053-9ECEBF58-0193-458B-9582-65D906DC4F95 Q35910923-0B957900-86A3-47CD-ADF9-A987D16FC351 Q35939801-6AF95122-C293-40C6-AC2A-2F9A600E007D Q36299317-95D0959C-AD23-41A5-935B-9A67EC5E0B20 Q36463140-4E37817D-D01C-44E7-82E7-32E481EDF6A3 Q36553735-0CBF0C53-14D4-4760-9E95-540D0ECE8D55 Q36696665-061C0C0D-268D-44EA-9C00-F51A164992F2 Q36725034-3F2FD151-E14E-4AD7-AC02-869F0D0E56E0 Q36843004-6D325B1D-B29D-40FF-B749-D54FFFF0D303 Q36885357-29ACCDDD-22A5-436E-90F1-6C990D97E8AA Q36934154-B6E6528D-6D55-49E3-99BA-8514DA7A96BA Q36974723-BF30088D-1017-493F-A6C4-9DF3DBFE88A6 Q37031336-B42954D7-9364-4C36-9CD7-24423B5A5CCF Q37100074-8B4C80BB-1B70-4E0F-B385-D399E5A45F2A Q37459258-43DC8B18-D98A-480E-B3DF-CE6649E813EF Q37520832-38E1D776-A13C-4010-93FF-7642E94A7C6B Q37670673-960E75B3-2AFD-4CCC-A523-3C2CFCD9240F

P2860

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

http://www.wikidata.org/entity/Q34422469

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

@ast

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

@en

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

@nl

type

label

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

@ast

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

@en

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

@nl

prefLabel

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

@ast

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

@en

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

@nl

P1433

Q34422469-E8D2041C-3034-49B8-9B3D-C15B8D7527A3

P1476

Q34422469-0DBFE7F8-DE31-4320-81D8-8B49FF136D97

P2093

Q34422469-387215F1-F14B-4EA1-A564-DEA38586BAC0

Q34422469-705D749D-C163-4A36-B09A-410FFEEF39C1

Q34422469-7655B67B-E69A-4427-9264-7B8650736534

Q34422469-90BF0DFD-B1D6-44A1-BBA0-49D40B0CA8C0

Q34422469-A2D32797-99CF-4D6A-9A41-5E1DCAF681FA

Q34422469-AF4C696D-438D-4466-B76A-7572059E4206

Q34422469-AFCBBAB5-93C2-4E06-AB0B-D10EDB0B224B

P2860

Q34422469-07ADEECA-C501-4FDE-AEDD-EE033CF5C082

Q34422469-1138C47B-C115-4EFF-AF9B-4C5B97D2B486

Q34422469-115DDFF6-0CFE-4D59-84B6-08B706A77467

Q34422469-136C5F4D-7204-445A-8DA1-51A8B2F55993

Q34422469-17260DA7-BADA-4B84-93C9-D3053BAE6824

Q34422469-18FEA31D-9820-4E7E-8327-9EF7EF3DF24F

Q34422469-19AED3F0-5293-4360-AD3B-2A035BD893A2

Q34422469-1D96943A-B763-47B1-94C1-1586E1B5D2FC

Q34422469-1F6FE0DB-C836-4C94-9C93-6B607276D97D

Q34422469-23D200FC-F7E0-4BD4-9497-C574C8A545F0

P304

Q34422469-EBCC2219-3AFE-4BB9-901C-04FD96C3912C

P31

Q34422469-DD709DC8-6047-451D-871D-C50814811A0E

Q34422469-b0b0fa60-66cd-42ef-a866-3f7bce3cc08b

P356

Q34422469-90BEF80E-1BF2-4756-A788-9FD72ABE49BC

P407

Q34422469-3AEDDB2F-4E6F-4A85-B872-E45A540B6A2F

P433

Q34422469-7E60C9BA-27C8-486A-962B-558B44F62692

P478

Q34422469-F72D65E8-BB02-40F0-802C-D2C99BB88E11

P50

Q34422469-038D6F06-0953-4379-875A-D2949164A440

Q34422469-5F2A21FE-89D1-4A32-98F7-17B40727E67D

Q34422469-6D578C30-F30C-48D4-804C-EC5156B341F8

Q34422469-E155AC8A-5352-462D-9825-7FCEFB17C647

P577

Q34422469-317065C0-F0BD-438F-8818-643862911854

P698

Q34422469-6A009C07-BE17-4244-A6CD-59E4B7F78F2D

P921

Q34422469-F6A136BD-5B1F-495F-8427-DB30D4D203A3

P932

Q34422469-47DA9641-B567-4D6A-99E8-D88E1488330C

P356

JAMANEUROL.2014.803

P1433

P1476

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

@en

P2093

Alzheimer’s Disease Cooperative Study

http://www.w3.org/2001/XMLSchema#string

Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing

http://www.w3.org/2001/XMLSchema#string

David P Salmon

http://www.w3.org/2001/XMLSchema#string

Dorene M Rentz

http://www.w3.org/2001/XMLSchema#string

Reisa A Sperling

http://www.w3.org/2001/XMLSchema#string

Rema Raman

http://www.w3.org/2001/XMLSchema#string

Ronald G Thomas

http://www.w3.org/2001/XMLSchema#string

P2860

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

“Mini-mental state”

Testing the right target and right drug at the right stage

Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

Simultaneous inference in general parametric models

Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia.

Estimating long-term multivariate progression from short-term data.

P304

961-970

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMANEUROL.2014.803

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Michael Donohue

Alzheimer's Disease Neuroimaging Initiative

Michael W. Weiner

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24886908

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

4439182

http://www.w3.org/2001/XMLSchema#string